Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
By I. Anand, L. Fisher, Y. Chiang, R. Latini, S. Masson, A. Maggioni, R. Glazer, G. Tognoni, J. Cohn. Circulation, 2003
887 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Complementary and alternative medicine
View Paper: https://www.semanticscholar.org/paper/787150e4e926f33bbce7c37e011c90698292dd6f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- J. Cleland
- Gerasimos Filippatos
- E. Braunwald
- S. Anker
- C. Yancy
- M. Gheorghiade
- Véronique L. Roger
Citations in the corpus
- State of the art: Using natriuretic peptide levels in clinical practice (2008, methodology): “In the Valsartan Heart Failure Trial (ValHeFT) and CARE-HF studies, changes in BNP over time induced by pharmacological or device therapy were shown to predict morbidity and mortality better than initial values [92,93].”
- Natriuretic peptides. (2007, methodology): “In an evaluation of al-HeFT (Valsartan Heart Failure Trial) comprising ,300 outpatients with chronic HF, those with the greatest ncrease in BNP despite therapy had the highest morbidity nd mortality (74).”